Mitochondrial ultrastructure-associated chemotherapy response in ovarian cancer

Oncology Reports

Volumn 21, Issue 1, 2009, Pages 199-204

  Saitou, Motoaki ^a   Isonishi, Seiji ^a,b   Hamada, Tomomi ^a   Kiyokawa, Takako ^a   Tachibana, Toshiaki ^a   Ishikawa, Hiroshi ^a   Yasuda, Makoto ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Jikei University Katsushika Medical Center   (Japan)

Author keywords

Cisplatinum sensitivity; Mitochondrial ultrastructure; Ovarian carcinoma

Indexed keywords

PLATINUM COMPLEX; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER STAGING; CARCINOMA CELL; CELL ULTRASTRUCTURE; CHEMOSENSITIVITY; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; ELECTRON MICROSCOPY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MITOCHONDRION; OVARY CANCER; PRIORITY JOURNAL; RECURRENT CANCER; SCORING SYSTEM; AREA UNDER THE CURVE; DRUG EFFECT; DRUG RESISTANCE; MIDDLE AGED; OVARY TUMOR; ROC CURVE; TRANSMISSION ELECTRON MICROSCOPY; ULTRASTRUCTURE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MICROSCOPY, ELECTRON, TRANSMISSION; MIDDLE AGED; MITOCHONDRIA; OVARIAN NEOPLASMS; ROC CURVE;

EID: 61449446547     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000208     Document Type: Article

References (18)

1. Andrews PA and Howell SB: Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cell 2: 35-43, 1990.
2. Sorenson CM and Eastman A: Influence of cis-diammine-dichloroplatinum (II) on DNA synthesis and cell cycle progression in excision repair proficient and deficient Chinese hamster ovary cells. Cancer Res 48: 6703-6707, 1988.
3. Eastman A: Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cell 2: 275-280, 1990.
4. Gonzalez VM, Fuertes MA, Alonso C and Perez JM: Is cisplatin-induced cell death always produced by apoptosis? Mol Pharmacol 59: 657-663, 2001.
5. Isonishi S, Saitou M, Yasuda M and Tanaka T: Mitochondria in platinum resistant cells. Hum Cell 14: 203-210, 2001.
6. Hirama M, Isonishi S, Yasuda M and Ishikawa H: Characterization of mitochondria in cisplatin resistant human ovarian carcinoma cells. Oncol Rep 16: 997-1002, 2006.
7. Kim T-S, Yun BY and Kim IY: Induction of the mitochondrial permeability transition by selenium compounds mediated by oxidation of the protein thiol groups and generation of the superoxide. Biochem Pharmacol 66: 2301-2311, 2003.
8. Chilin A, Dodoni G, Frezza C, Guiotto A, Barbieri V, Di Lisa F, and Canton M: 4-hydroxymethyl-1,6,8-trimethylfuro [2,3-h] quinolin-2(1H)-one induces mitochondrial dysfunction and apoptosis upon its intracellular oxidation. J Med Chem 48: 192-199, 2005.
9. Isonishi S, Saitou M, Ochiai K, Yasuda M and Tanaka T: Enhancement of sensitivity to cisplatin by orobol is associated with increased mitochondrial cytochrome c release in human ovarian carcinoma cells. Gynecol Oncol 90: 413-420, 2003.
10. Silverberg SG: Histopathologic grading of ovarian carcinoma: A review and proposal. Int J Gynecol Pathol 19: 7-15, 2000.
11. McCluggage WG, Lyness RW, Atkinson RJ, et al: Morphological effects of chemotherapy on ovarian carcinoma. J Clin Pathol 55: 27-31, 2002.
12. Blaustein's Pathology of the Female Genital Tract. Kurman RJ (ed). 3rd edition, Springer-Verlag, Berlin, 1987.
13. Benda JA and Zaino R: GOG Pathology Manual. Gynecologic Oncology Group, Buffalo, NY, 1994.
14. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
15. Rustin GJ: Use of CA-125 to assess to response to new agents in ovarian cancer trials. J Clin Oncol 21 (Suppl 10): S187-S193, 2003.
16. Vasey PA, Paul J, Birt A, et al: Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer. J Clin Oncol 17: 2069-2080, 1999.
17. The International Collaborative Ovarian Neoplasm (ICON) Group: Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 360: 505-515, 2002.
18. Eisenhauer EA, Vermorken JB and van Glabbeke M: Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann Oncol 8: 963-968, 1997.